FORMATO EUROPEO PER IL CURRICULUM VITAE

Transcript

1 FORMATO EUROPEO PER IL CURRICULUM VITAE INFORMAZIONI PERSONALI Nome GIRBINO GIUSEPPE Telefono +39 (090) Fax Nazionalità ITALIANA Data di Nascita 25/09/1948 ESPERIENZA LAVORATIVA 30/07/ UNIVERSITA' DI MESSINA - FACOLTA' DIMEDICINA E CHIRURGIA, POLICLINICO UNIVERSITARIO MESSINA DIRETTORE DIRETTORE DI UNITÀ OPERATIVA COMPLESSA DI PNEUMOLOGIA 01/06/ /06/2009 UNIVERSITA' DI MESSINA - FACOLTA' DIMEDICINA E CHIRURGIA, POLICLINICO UNIVERSITARIO MESSINA DIRETTORE COORDINAMENTO DEL DIPARTIMENTO AD ATTIVITÀ INTEGRATA DI SCIENZE CARDIOVASCOLARI E TORACICHE(UUOOCC DI:CARDIOLOGIA, PNEUMOLOGIA, CHIRURGA TORACICA, CHIRURGIA VASCOLARE, CARDIOCHIRURGIA, TERAPIA INTENSIVA CARDIOLOGICA, EMODINAMICA) 01/01/ UNIVERSITA' DI MESSINA, POLICLINICO UNIVERSITARIO MESSINA DIRETTORE DIRETTORE N. 2 POSTI LETTO DI TERAPIA SUBINTENSIVA RESPIRATORIA 01/01/ UNIVERSITA' DI MESSINA FACOLTA' DIMEDICIANA E CHIRURGIA, POLICLINICO UNIVERSITARIO MESSINA DIRETTORE SETTORE DI ISOLAMENTO PER MALATTIE POLMONARI CONTAGIOSE 01/01/ UNIVERSITA' DI MESSINA, DIPARTIMENTO CLINICO SPERIMENTALE DIMEDICINA E FARMACOLOGIA RESPONSABILE

2 RESPONSABILE SEZIONE MALATTIE RESPIRATORIE 01/02/ UNIVERSITA' DI MESSINA FACOLTA' DI MEDICINA E CHIRURGIA, POLICLINICO UNIVERSITARIO MESSINA FUNZIONE PRIMARIALE ISTITUZIONE REPARTO CLINICA DI PNEUMOLOGIA 01/01/ UNIVERSITA' DI MESSINA FACOLTA' DI MEDICINA E CHIRURGIA, CORSO DILAUREA IN MEDICINA E CHIRURGIA COORDINATORE CORSO INTEGRATO DI MALATTIE DELL'APPARATO CARDIOVASCOLARE E RESPIRATORIO 01/01/ UNIVERSITA' DI MESSINA, CORSO DI LAUREA IN MEDICINA E CHIRURGIA COORDINATORE AREA VII NUOVA TABELLA XVIII 01/11/ UNIVERSITA' DI MESISNA FACOLTA' DIMEDICINA E CHIRURGIA, POLICLINICO UNIVERSITARIO MESSINA DIRETTORE INSEGNAMENTI DI DISCIPLINE RESPIRATORIE E COORDINAMENTO DELLE ATTIVITÀ DIDATTICHE 01/01/ UNIVERSITA' DEGLI STUDI DI MESSINA, POLICLINICO UNIVERSITARIO MESSINA FUNZIONE PRIMARIALE ISTITUTO DI TISIOLOGIA E MALATTIE RESPIRATORIE - ATTIVITA' ASSISTENZIALE CON ANNESSO SERVIZIO DI FISIOPATOLOGIA RESPIRATORIA 01/11/ UNIVERSITA' DI MESSINA, POLICLINICO UNIVERSITARIO MESSINA DIRETTORE SCUOLA DI SPECIALIZZAZIONE IN FISIOPATOLOGIA E FISIOKINESITERAPIA RESPIRATORIA 01/01/ UNIVERSITA' DI MESSINA, POLICLINICO UNIVERSITARIO MESSINA PROFESSORE ORDINARIO CORSO UFFICIALE DI INSEGNAMENTO MALATTIE RESPIRATORIE

3 01/11/ UNIVERSITA' DI MESSINA, POLICLINICO UNIVERSITARIO MESSINA PROFESSORE ASSOCIATO TISIOLOGIA E MALATTIE RESPIRATORIE 01/11/ UNIVERSITA' DI MESSINA, POLICLINICO UNIVERSITARIO MESSINA FUNZIONE PRIMARIALE REPARTI CLINICO DELL'ISTITUTO DI TISIOLOGIA, MALATTIE RESPIRATORIE E FISIOPATOLOGIA RESPIRATORIA - OSPEDALE PUGLISI ALLEGRA - MESSINA - REPARTI DI TISIOLOGIA E MALATTIE RESPIRATORIE 01/11/ UNIVERSITA' DI MESSINA, FACOLTA' DI MEDICINA E CHIRURGIA INSEGNAMENTO UNIVERSITARIO CORSI UFFICIALI AGLI STUDENTI DEL SECONDO TRIENNIO DI FISIOPATOLOGIA E DI TISIOLOGIA E MALATTIE RESPIRATORIE 01/11/ /10/1989 UNIVERSITA' DIMESSINA, FACOLTA' DI MEDICINA E CHIRURGIA INSEGNAMENTO UNIVERSITARIO SCUOLA DI SPECIALIZZAZIONE IN TISIOLOGIA E MALATTIE RESPIRATORIE - INSEGNAMENTO DI TISIOLOGIA E MALATTIE RESPIRATORIE 01/11/ UNIVERSITA' DI MESSINA, FACOLTA' DI MEDICINA E CHIRURGIA RESPONSABILITÀ PRIMARIALE SERVIZIO DI FISIOPATOLOGIA RESPIRATORIA 01/11/ UNIVERSITÀ DI MESSINA, OSPEDALE S. PUGLISI ALLEGRA MESSINA DIRETTORE ISITITUTO DI TISIOOGIA, MALATTIE RESPIRATORIE FISIOPTALOTOGIA RESPIRATORIA - SERVIZIO DI BRONCOLOGIA CLINICA E FUINZIONALE DEI REPARTI CLINICI 01/11/ UNIVERSITA' DI MESSINA, FACOLTÀ DI MEDICINA E CHIRURGIA PROFESSORE INCARICATO FISIOPATOLOGIA RESPIRATORIA

4 01/11/ UNIVERSITA' DI MESSINA, FACOLTA' DI MEDICINA E CHIRURGIA AIUTO DIRETTORE ISTITUTO DI TISIOLOGIA, MALATTIE RESPIRATORIE E FISIOPATOLOGIA RESPIRATORIA 01/11/ /10/1976 UNIVERSITÀ DIMESSINA, FACOLTÀ DIMEDICINA E CHIRURGIA ALTRO INSEGNAMENTO UNIVERSITARIO SCUOLA DI SPECIALIZZAZIONE IN TISIOLOGIA - BRONCOLOGIA 15/07/ UNIVERSITÀ DI MESSINA, FACOLTÀ DI MEDICINA E CHIRURGIA ALTRO ASSISTENTE ORDINARIO ISTITUTO DI CLINICA TISIOLOGICA, MALATTIE RESPIRATORIE E FISIOPATOLOGIA RESPIRATORIA - FISIOPATOLOGIA RESPIRATORIA 01/11/ UNIVERSITA' DI MESSINA, FACOLTÀ DI MEDICINA E CHIRURGIA BORSISTA ISTITUTO DI CLINICA TISIOLOGICA, MALATTIE RESPIRATORIE E FISIOPATOLOGIA RESPIRATORIA - FISIOPATOLOGIA RESPIRATORIA ISTRUZIONE E FORMAZIONE 01/11/ /10/1981 Nome e tipo di istituto di istruzione o formazione UNIVERSITA' DI MESSINA, MESSINA - ITALIA di Studio SPEC.NE IN IGIENE E MED. PREVENT. - ORIENT. PUBBLICA Qualifica conseguita SPECIALISTA Livello nella classificazione nazionale 50/50 CON LODE 01/11/ /10/1975 Nome e tipo di istituto di istruzione o formazione UNIVERSITA' DI MESSINA, MESSINA - ITALIA di Studio SPEC.NE IN TISIOLOGIA E MALATTIE DELL'APPARATO RESPIRATORIO Qualifica conseguita SPECIALISTA Livello nella classificazione nazionale 50/50 CON LODE 01/11/ /11/1972 Nome e tipo di istituto di istruzione o formazione UNIVERSITA' DI MESSINA, MESSINA - ITALIA di Studio LAUREA IN MEDICINA E CHIRURGIA Qualifica conseguita SPECIALISTA Livello nella classificazione nazionale 110/110 CON LODE

5 01/10/ /06/1966 Nome e tipo di istituto di istruzione o formazione LICEO VITTORIO ENAMUELE III PATTI (ME), PATTI (ME) - ITALIA di Studio MATURITA' CLASSICA Qualifica conseguita MATURITA' CLASSICA Livello nella classificazione nazionale PUBBLICAZIONI CLOSE CORRELATION BETWEEN ANXIETY, DEPRESSION, AND ASTHMA CONTROL. DI MARCO F, VERGA M, SANTUS P, GIOVANNELLI F, BUSATTO P, NERI M, GIRBINO G, BONINI S, CENTANNI S.. BACKGROUND: WE INVESTIGATED THE CORRELATION BETWEEN PATIENTS' CHARACTERISTICS, INCLUDING ANXIETY AND DEPRESSION, AND THE LEVEL OF ASTHMA CONTROL EVALUATED BY ASTHMA CONTROL TEST (ACT), A SELF-ADMINISTERED VALIDATED QUESTIONNAIRE. METHODS: THIS IS A CROSS-SECTIONAL STUDY ON ASTHMATIC OUTPATIENTS OF THREE ITALIAN HOSPITALS. DEMOGRAPHIC DATA, SPIROMETRY, ANXIETY AND DEPRESSION SCORES AS WELL AS THE LEVEL OF ASTHMA CONTROL FROM 315 PATIENTS WERE COLLECTED. RESULTS: PATIENTS WITH POORLY CONTROLLED ASTHMA WERE MORE FREQUENTLY WOMEN, OLDER, WITH A WORSE PULMONARY FUNCTION, OBESE, MORE ANXIOUS AND/OR MORE DEPRESSED. FOUR DIFFERENT INDEPENDENT FACTORS ASSOCIATED WITH POOR ASTHMA CONTROL EVALUATED BY ACT HAVE BEEN FOUND: FEV(1)<60% (ODDS RATIO, OR: 6.52), ANXIETY (OR: 3.76), AGE >/=65YEARS (OR: 2.69), AND DEPRESSION (OR: 2.45). THE PRESENCE OF ANXIETY AND DEPRESSION WAS ASSOCIATED WITH A HIGHER HEALTHCARE UTILIZATION. FINALLY, WE FOUND A HIGH LEVEL OF AGREEMENT BETWEEN ACT AND MULTIDIMENSIONAL GINA APPROACH IN EVALUATING ASTHMA CONTROL, WITH A CONCORDANCE IN 239 PATIENTS (81% OF THE POPULATION). CONCLUSION: THERE IS A CLOSE CORRELATION BETWEEN ANXIETY AND DEPRESSION, AND A POOR ASTHMA. A BETTER UNDERSTANDING OF THIS ASSOCIATION MAY HAVE MAJOR CLINICAL IMPLICATIONS, MAINLY IN PATIENTS WITH POOR CONTROLLED ASTHMA IN WHOM THE PRESENCE OF ANXIETY AND DEPRESSION SHOULD BE INVESTIGATED. RESPIR MED SEP 2 ANNO: ISBN: TIOTROPIUM AND SALMETEROL/FLUTICASONE COMBINATION DO NOT CAUSE OXYGEN DESATURATION IN COPD ANDÒ F, RUGGERI P, GIRBINO G, CAZZOLA M. IT HAS BEEN DOCUMENTED THAT TIOTROPIUM IS LESS LIKELY TO INDUCE OXYGEN DESATURATION IN STABLE COPD PATIENTS COMPARED TO LONG-ACTING BETA2-AGONISTS (LABAS) AND COMBINED ADMINISTRATION OF A LABA AND AN INHALED CORTICOSTEROID (ICS) REDUCES THE POTENTIAL FOR ACUTE EFFECTS OF LABA ON BLOOD-GAS TENSIONS. IN THIS STUDY, WE HAVE COMPARED THE ACUTE EFFECTS OF TIOTROPIUM 18 MICROG AND SALMETEROL/FLUTICASONE COMBINATION (SFC) 50/250 MICROG ON ARTERIAL BLOOD GASES IN 20 PATIENTS WITH STABLE COPD. EACH SUBJECT WAS STUDIED ON 2 DAYS, SEPARATED FROM ONE ANOTHER BY AT LEAST 4 DAYS. BLOOD SPECIMENS WERE TAKEN JUST BEFORE THE INHALATION AND AT 15, 30, 60, 180 AND 360 MIN AFTER INHALATION OF EACH TREATMENT, AND SPIROMETRY WAS PERFORMED AT THE SAME TIME POINTS. AS EXPECTED, BOTH TREATMENTS SIGNIFICANTLY IMPROVED FEV1 (GREATEST CHANGES WERE 0.20 L, 95% CI: AT 360 MIN AFTER TIOTROPIUM; AND 0.13 L, 95% CI: AT 180 MIN AFTER SFC). THE GREATEST MEAN CHANGES FROM BASELINE IN PAO2 WERE -1.7 (95% CI: -4.0 TO 0.6)MMHG, P=0.134, AFTER TIOTROPIUM; -0.8 (95% CI: -2.2 TO 0.6)MMHG, AFTER SFC. BOTH CHANGES WERE OBSERVED AFTER 15 MIN. BOTH DRUGS CAUSED A SMALL DECREASE IN PACO2 (GREATER CHANGES: -1.9 (95% CI -3.2 TO -0.6)MMHG, P=0.005 AT 60 MIN AFTER TIOTROPIUM; AND -2.4 (95% CI: -3.5 TO -1.3) MMHG, P= AT 180 MIN AFTER SFC). THESE RESULTS INDICATE THAT BOTH TIOTROPIUM AND SFC ARE ABLE TO INDUCE A SIGNIFICANT LONG-LAST BRONCHODILATION WITHOUT AFFECTING ARTERIAL BLOOD GASES. MOREOVER, THEY CONFIRM THAT THE IMPACT OF TIOTROPIUM ON PAO2 IS SMALL AND WITHOUT CLINICAL SIGNIFICANCE AND THE ADDITION OF A LABA TO AN ICS CAN REDUCE THE POTENTIALLY DANGEROUS ACUTE EFFECT OF THE LABA ON BLOOD GASES. RESPIR MED JUN;102(6): EPUB 2008 MAR 17. ANNO: ISBN: DIABETE E APPARATO RESPIRATORIO ASSOCIAZIONE DIABETE-BPCO PAOLO RUGGERI, UMBERTO ALECCI, GIUSEPPE GIRBINO LA BPCO E IL DIABETE MELLITO COSTITUISCONO, SOTTO IL PROFILO EPIDEMIOLOGICO, DUE ENTITÀ NOSOLOGICHE IN COSTANTE E SIGNIFICATIVO INCREMENTO. COINVOLGONO PIÙ FREQUENTEMENTE ADULTI IN ETÀ AVANZATA E RISULTANO SPESSO ASSOCIATE. LO STUDIO DI TALE ASSOCIAZIONE RISULTA DI FONDAMENTALE IMPORTANZA NEL COMPRENDERE DA UN LATO LE POSSIBILI CONNESSIONI SOTTO IL PROFILO EZIOPATOGENETICO, E DALL ALTRO, SOTTO IL PROFILO CLINICO, LE

6 RIPERCUSSIONI IN TERMINI DI DIAGNOSI E MODIFICAZIONI DELL APPROCCIO TERAPEUTICO SPECIALMENTE PER CIÒ CHE CONCERNE LA POSSIBILITÀ DI UTILIZZARE LA TERAPIA CON CORTICOSTEROIDI PER VIA INALATORIA NELLA FASE DI STABILITÀ DELLA BPCO E SISTEMICA IN CORSO DI GRAVI RIACUTIZZAZIONI. IL LINK PATOGENETICO TRA QUESTE DUE PATOLOGIE SEMBRA ESSERE RAPPRESENTATO DALL INFIAMMAZIONE SISTEMICA, OGGI SEMPRE MEGLIO CARATTERIZZATA IN CORSO DI BPCO, CHE MEDIANTE L AZIONE DI SPECIFICHE CITOCHINE (TNF-ALFA E IL-6) POTREBBE SPIEGARE LA PIÙ PROBABILE COMPARSA DI DIABETE IN CORSO DI BPCO. LE LINEE GUIDA ATTUALI DELLE DUE PATOLOGIE NON TENGONO IN DEBITO CONTO LA POSSIBILITÀ DI TALE ASSOCIAZIONE, SEBBENE SEMPRE MAGGIORE INTERESSE VENGA OGGI RIVOLTO AL RUOLO DELLE COMORBIDITÀ NELLA BPCO CHE, SI È VISTO,SONO IN GRADO DI MODIFICARE IN MANIERA SIGNIFICATIVA LA STORIA NATURALE DELLA MALATTIA STESSA INCIDENDO SU OUTCOME IMPORTANTI COME LA MORTALITÀ. SFORZI CONDIVISI TRA SPECIALISTI DA UN LATO (PNEUMOLOGI ED ENDOCRINOLOGI) E MEDICI DI MEDICINA GENERALE (ATTENTI OSSERVATORI DI TALE FENOMENO) DALL ALTRO SONO NECESSARI AL FINE DI INDIVIDUARE MODALITÀ DI APPROCCIO DIAGNOSTICO E MANAGEMENT TERAPEUTICO PER TRATTARE ADEGUATAMENTE IL PAZIENTE E NON LE SINGOLE PATOLOGIE. MEDIA 2008;8: ANNO: ISBN: BRONCHITE CRONICA, BPCO ED ENFISEMA IN MALATTIE RESPIRATORIE: L'ESSENZIALE G.GIRBINO, P.RUGGERI MALATTIE RESPIRATORIE: L ESSENZIALE. ELSEVIER. SETTEMBRE 2008 (PP.39-67) ANNO: ISBN: LE MALFORMAZIONI POLMONARI CONGENITE. IN: PAOLO LARIZZA. MANUALE DI MEDICINA INTERNA. G.GIRBINO, P.RUGGERI MANUALE DI MEDICINA INTERNA. (VOL. 1, PP ) ANNO: ISBN: BPCO:TERAPIA CORTISONICA NEI PAZIENTI DIABETICI RUGGERI P., ALECCI U, GIRBINO G. MEDIA. VOL. 8, PP ANNO: ISBN: COMPARATIVE EFFECTS OF A TWO-WEEK TREATMENT WITH NEBIVOLOL AND NIFEDIPINE IN HYPERTENSIVE PATIENTS SUFFERING FROM COPD CAZZOLA M, MATERA MG, RUGGERI P, SANDUZZI A, SPICUZZA L, VATRELLA A, GIRBINO G. BACKGROUND: IT HAS BEEN SUGGESTED THAT THE ANTIHYPERTENSIVE AGENT NEBIVOLOL, A BETA1- ADRENOCEPTOR-BLOCKING AGENT THAT MODULATES THE ENDOGENOUS PRODUCTION OF NITRIC OXIDE, IS PREFERABLE TO 'CONVENTIONAL' BETA1-BLOCKERS IN HYPERTENSIVE PATIENTS WITH AIRWAY DYSFUNCTION. OBJECTIVES: SINCE BETA1-BLOCKADE BY NEBIVOLOL IS LARGER AFTER REPEATED DOSING THAN AFTER A SINGLE ORAL INTAKE, WE HAVE EXPLORED ITS EFFECT ON PULMONARY FUNCTION AFTER A 2-WEEK TREATMENT IN HYPERTENSIVE PATIENTS WITH MILD TO MODERATE COPD. METHODS: A SINGLE-BLIND CROSSOVER DESIGN WAS USED. TWENTY PATIENTS WITH COPD AS SELECTED ABOVE AND WITH A DIASTOLIC BLOOD PRESSURE OF MM HG AFTER 1 WEEK OF PLACEBO RUN-IN WERE ENTERED INTO THE TWO 2-WEEK ACTIVE TREATMENT PERIODS WITH EITHER 5 MG NEBIVOLOL (N = 10) OR 30 MG NIFEDIPINE GASTROINTESTINAL-TRANSPORT- SYSTEM (GITS) (N = 10) TAKEN FOR A PERIOD OF 2 WEEKS. AFTER A FURTHER 1-WEEK WASHOUT, SUBJECTS WERE CROSSED-OVER TO RECEIVE THE OTHER DRUG FOR 2 ADDITIONAL WEEKS. AT EACH VISIT, CHANGES IN SPIROMETRIC INDEXES AND THE INTERACTION WITH THE BRONCHODILATOR EFFECT OF SALBUTAMOL WERE INVESTIGATED. MOREOVER, SYSTOLIC AND DIASTOLIC BLOOD PRESSURE (BP) TOGETHER WITH HEART RATE WERE MANUALLY MEASURED IN ORDER TO EVALUATE THE CARDIOVASCULAR EFFECTS OF THE DIFFERENT TREATMENTS. THROUGHOUT THE STUDY, PATIENTS RECORDED SYMPTOMS. RESULTS: SIMILAR AND SIGNIFICANT REDUCTIONS IN SYSTOLIC AND DIASTOLIC BP WERE OBSERVED WITH BOTH TREATMENTS. THE IMPACT OF NIFEDIPINE ON FEV1 WAS NOT SIGNIFICANT (P > 0.05), WHILE THAT OF NEBIVOLOL WAS SLIGHT. THE MAXIMUM RESPONSE TO SALBUTAMOL WAS SLIGHTLY DECREASED WITH EITHER NEBIVOLOL OR NIFEDIPINE GITS. DAY-TO-DAY AIRWAY OBSTRUCTION CONTROL, INTERPRETED FROM PATIENT RECORDINGS OF SYMPTOM SCORES AND INHALER USE, WAS SIMILAR WITH BOTH TREATMENTS. CONCLUSIONS: OUR PILOT STUDY SUGGESTS THAT THE USE OF NEBIVOLOL IN HYPERTENSIVE PATIENTS WITH STABLE MILD TO MODERATE COPD WAS SAFE DURING A 2-WEEK

7 TRIAL. EVALUATION OF LONGER TIME PERIODS, LARGER PATIENT NUMBERS WITH MORE SEVERE COPD OR DURING EXACERBATIONS IS WARRANTED RESPIRATION MAR-APR;71(2): ANNO: ISBN: IMBALANCE OF SERUM CYTOKINE NETWORK IN SARCOID PATIENTS: INDEX OF SARCOIDOSIS RELAPSE? SALMERI FM, SOFO V, ANDÒ FG, VASTOLA MB, CROSCA S, BITTO A, GAETA M, GIRBINO G. BACKGROUND AND AIM OF THE WORK: THE FOLLOW-UP OF SARCOIDOSIS IS USUALLY PERFORMED BY INVASIVE TOOLS SUCH AS THORACIC BIOPSY, SUPPORTED BY BRONCHO-ALVEOLAR LAVAGE (BAL), GALLIUM-SCINTIGRAPHY AND GADOLINIUM MAGNETIC RESONANCE IMAGING (GD-MRI) TO EVALUATE THE DEGREE OF DISEASE. ITS PATHOGENESIS CAN BE ASCRIBED TO AN ACCUMULATION OF CELLS DUE TO THE DISREGULATION OF THE IMMUNE SYSTEM WHICH INVOLVES TH1/TH2 CELLS AS WELL AS THE SOLUBLE FACTORS THEY GENERATE. WE EVALUATED SERUM CYTOKINE AND MEMBRANE MARKER LEVELS (CYTOKINE NETWORK) IN SARCOID PATIENTS IN ORDER TO STUDY THE CORRELATION WITH THE DISEASE ACTIVITY, IN PARTICULAR WITH THE OCCURRENCE OF SARCOIDOSIS RELAPSES. PATIENTS AND METHODS: SEVEN SARCOID PATIENTS CLINICALLY STABLE WITHOUT THERAPY, AT DIFFERENT STAGES, WERE ENROLLED IN OUR STUDY. CYTOKINE AND MEMBRANE MARKER SERUM VALUES WERE MEASURED MONTHLY FOR 24 MONTHS, AFTER A SIX- MONTH PERIOD OF RUN-IN, BY ELISA ASSAY AND MOAB INDIRECT IMMUNOFLUORESCENCE, RESPECTIVELY. RESULTS: IN SOME PATIENTS AT THE FIRST AND SECOND STAGES OF THE DISEASE WE OBSERVED MCP-1 AND INFLAMMATORY CYTOKINE PEAKS AND, MOREOVER, MCP-1 VALUES WERE INCREASED BEFORE OTHER CYTOKINE VALUES. AFTER THREE SUBSEQUENT INCREASES OF THESE PARAMETERS WERE OBSERVED, ACCORDING TO OUR PERSONAL EXPERIENCE, GADOLINIUM-MRI CONFIRMED THE PRESENCE OF AN INCREASE OF THE LESION AND THEREFORE OUR HYPOTHESIS OF SARCOIDOSIS RELAPSE. ONLY ONE PATIENT AT STAGE III SHOWED CONSTANTLY ELEVATED VALUES OF FIBRO-ANGIOGENIC CYTOKINES AND MEMBRANE RECEPTORS OF THE TNF RECEPTOR FAMILY. CONCLUSIONS: CYTOKINE NETWORK MONITORING COULD BE A NON-INVASIVE MEANS OF FOLLOWING UP THE CLINICAL COURSE OF SARCOIDOSIS. SARCOIDOSIS VASC DIFFUSE LUNG DIS MAR;20(1): ANNO: ISBN: LE PNEUMOPATIE DA FATTORI AMBIENTALI G.GIRBINO P.RUGGERI MEDICINA CLINICA BASI BIOLOGICHE DIAGNOSTICA TERAPIA ED. MEDICO SCIENTIFICHE TORINO 1-36,6 ID ANNO: ISBN: LE MALATTIE PROFESSIONALI DEL POLMONE G.GIRBINO P. RUGGERI LUCIO CASALI MANUALE DI MALATTIE DELL APPARATO RESPIRATORIO. MASSON ITALIA , 1 ID ANNO: ISBN: AN OBSERVATIONAL STUDY ON THE EPIDEMIOLOGY OF RESPIRATORY TRACT BACTERIAL PATHOGENS AND THEIR SUSCEPTIBILITY TO FOUR INJECTABLE BETA-LACTAM ANTIBIOTICS: PIPERACILLIN, PIPERACILLIN/TAZOBACTAM, CEFTAZIDIME AND CEFTRIAXONE. VAROTTO F, MARIA GD, AZZARO R, BELLISSIMA P, AMATO R, FOGLIANI V, MUSCIANISI G, VITALE S, GIRBINO G, ANDÒ F, LAGANÀ P, DELIA S, JACOVIELLO C, MAIERNA G, PEZZA A, COVELLI I, MAGRÌ M, NAPOLETANO G, ROSSI A, MARONE P, SANGUINETTI C, PELA R, TEDESCHI D, BACTERIAL INFECTIONS OF THE RESPIRATORY TRACT ACCOUNT FOR A LARGE PROPORTION OF TOTAL MEDICAL CONSULTATIONS IN GENERAL PRACTICE. IN RECENT YEARS, ANTIBIOTIC RESISTANCE HAS INCREASED ALARMINGLY IN A NUMBER OF BACTERIAL SPECIES THAT ARE COMMON CAUSES OF THESE INFECTIONS. THE AIM OF THIS OBSERVATIONAL STUDY WAS TO DETERMINE THE ANTIBIOTIC RESISTANCE OF MICROBIAL AGENTS ISOLATED FROM PATIENTS WITH ACUTE OR ACUTELY EXACERBATED RESPIRATORY INFECTIONS. SUBJECTS RECRUITED AS POTENTIAL SOURCES OF BACTERIA WERE EITHER OUTPATIENTS SEEN IN A NUMBER OF SPECIALIZED CLINICS AND HOSPITAL PRACTICES, OR HOSPITALIZED PATIENTS. OVERALL, 648 CONSECUTIVE PATIENTS (67% MALE, MEAN AGE 48.1+/-27.0 YEARS) WITH INFECTION OF THE UPPER OR LOWER RESPIRATORY TRACT WERE OBSERVED DURING A 13-MONTH PERIOD. A TOTAL OF 551 PATHOGENIC MICROBIAL STRAINS WERE ISOLATED AND TESTED FOR THEIR IN VITRO SUSCEPTIBILITY TO PIPERACILLIN, PIPERACILLIN/TAZOBACTAM, CEFTAZIDIME, AND CEFTRIAXONE. AMONG ALL ISOLATES, THE FOUR

8 MOST FREQUENT PATHOGENS WERE PSEUDOMONAS AERUGINOSA (132 ISOLATES, 24%), STREPTOCOCCUS PYOGENES (99 ISOLATES, 18%), STAPHYLOCOCCUS AUREUS (93 ISOLATES, 17%), AND KLEBSIELLA PNEUMONIAE (46 ISOLATES, 8%). THE SUSCEPTIBILITY OF GRAM-POSITIVE ISOLATES RANGED FROM 97.5% TO 95.1%, AND NO REMARKABLE DIFFERENCE WAS FOUND IN THE ANTIBACTERIAL ACTIVITY OF TESTED B-LACTAM ANTIBIOTICS. THE SUSCEPTIBILITY OF GRAM- NEGATIVE ISOLATES TO PIPERACILLIN AND PIPERACILLIN/TAZOBACTAM WAS ALSO SIMILAR: 96.5% AND 97.1%, RESPECTIVELY. IN CONTRAST, DIFFERENCES WERE FOUND BETWEEN PIPERACILLIN (OR PIPERACILLIN/TAZOBACTAM) AND EITHER CEFTAZIDIME (P=0.003) OR CEFTRIAXONE (P<0.0003) IN GRAM-NEGATIVE ISOLATES. WE CONCLUDE THAT, DESPITE THE EXTENSIVE USE OF BETA-LACTAM ANTIBIOTICS (PIPERACILLIN, CEFTAZIDIME, AND CEFTRIAXONE) IN MEDICAL PRACTICE DURING THE PAST THREE DECADES, THE SUSCEPTIBILITY OF THE MOST COMMON PATHOGENS INVOLVED IN THE ETIOLOGY OF UPPER AND LOWER RESPIRATORY TRACT INFECTIONS TO THESE ANTIBIOTICS IS STILL HIGH. IN PARTICULAR, BACTERIAL RESISTANCE DEVELOPED BY GRAM-POSITIVE ORGANISMS AGAINST PIPERACILLIN IS NEGLIGIBLE AND NOT ALARMING. J CHEMOTHER AUG;13(4): ANNO: ISBN: EFFECTS OF FORMOTEROL, SALMETEROL OR OXITROPIUM BROMIDE ON AIRWAY RESPONSES TO SALBUTAMOL IN COPD. CAZZOLA M, DI PERNA F, NOSCHESE P, VINCIGUERRA A, CALDERARO F, GIRBINO G, MATERA MG. WE EXAMINED WHETHER A PRETREATMENT WITH FORMOTEROL, OXITROPIUM BROMIDE, OR SALMETEROL MIGHT MODIFY THE DOSE-RESPONSE CURVES TO INHALED SALBUTAMOL IN PATIENTS WITH STABLE AND PARTIALLY REVERSIBLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). SIXTEEN OUTPATIENTS WITH PARTIALLY REVERSIBLE, STABLE COPD RECEIVED 24 MICROG FORMOTEROL, 50 MICROG SALMETEROL, 200 MICROG OXITROPIUM BROMIDE, OR PLACEBO ON FOUR NON-CONSECUTIVE DAYS. SPIROMETRIC TESTING WAS PERFORMED IMMEDIATELY BEFORE INHALATION OF TREATMENT AND AFTER 2 H. A DOSE-RESPONSE CURVE TO INHALED SALBUTAMOL WAS THEN CONSTRUCTED USING DOSES OF 100, 100, 200 MICROG AND 400 MICROG--THAT IS, A TOTAL CUMULATIVE DOSE OF 800 MICROG. DOSE INCREMENTS WERE GIVEN AT 20 MIN INTERVALS WITH MEASUREMENTS BEING MADE 15 MIN AFTER EACH DOSE. FORMOTEROL, SALMETEROL, OR OXITROPIUM BROMIDE ELICITED A SIGNIFICANT INCREASE IN FORCED EXPIRATORY VOLUME IN ONE SECOND (FEV1) COMPARED WITH PLACEBO (MEAN DIFFERENCES (L) = PLACEBO 0.05; FORMOTEROL 0.34; SALMETEROL 0.27; OXITROPIUM BROMIDE 0.23). DOSE-DEPENDENT INCREASES IN FEV1 WERE SEEN (MEAN VALUES (L) BEFORE SALBUTAMOL AND AFTER A CUMULATIVE DOSE OF 100, 200, 400, AND 800 MICROG = PLACEBO: 1.06, 1.28, 1.35, 1.39, 1.41; FORMOTEROL: 1.33, 1.37, 1.41, 1.44, 1.44; SALMETEROL: 1.30, 1.33, 1.36, 1.39, 1.42; OXITROPIUM BROMIDE: 1.27, 1.34, 1.37, 1.41, 1.40). STATISTICAL ANALYSIS REVEALED NO SIGNIFICANT DIFFERENCES IN FEV1 AND FORCED VITAL CAPACITY (FVC) RESPONSES TO SALBUTAMOL AFTER THERAPY WITH FORMOTEROL, SALMETEROL, OR OXITROPIUM BROMIDE COMPARED WITH PLACEBO. THIS STUDY CLEARLY SHOWS THAT A PRETREATMENT WITH A CONVENTIONAL DOSE OF FORMOTEROL, SALMETEROL, OR OXITROPIUM BROMIDE DOES NOT PRECLUDE THE POSSIBILITY OF INDUCING A FURTHER BRONCHODILATION WITH SALBUTAMOL IN PATIENTS SUFFERING FROM PARTIALLY REVERSIBLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE. EUR RESPIR J JUN;11(6): ANNO: ISBN: BECLOMETHASONE DIPROPIONATE GIVEN TO ADULT ASTHMATICS THROUGH A NEW SPACER DEVICE: EFFECTS OF HIGH-DOSE ADMINISTRATION. GIRBINO G, LAURIELLO G, ANDÓ F, CANTINI L. THE USEFULNESS OF A METERED-DOSE INHALER EQUIPPED WITH A NEW SPACER DEVICE (JET SPACER) WAS EVALUATED AND COMPARED WITH THAT OF A STANDARD ACTUATOR IN THE ADMINISTRATION OF HIGH-DOSE INHALED BECLOMETHASONE DIPROPIONATE (0.5 MG FOUR TIMES DAILY) TO ADULTS WITH MODERATE ASTHMA. AFTER A 2-WEEK RUN-IN PERIOD, 36 PATIENTS WERE ENROLLED IN A 4-WEEK STUDY ACCORDING TO A RANDOMIZED, PARALLEL-GROUP DESIGN. EFFICACY WAS ASSESSED BY MEASUREMENTS OF PULMONARY FUNCTION AND DAILY BETA 2-AGONIST CONSUMPTION. MORNING SERUM AND 24-HOUR URINARY CORTISOL LEVELS WERE MEASURED AT BASELINE AND AFTER TREATMENT; ADRENOCORTICOTROPIC HORMONE (ACTH) STRESS TESTING WAS ALSO DONE. SPIROMETRIC PARAMETERS SIGNIFICANTLY IMPROVED IN BOTH GROUPS; PEAK EXPIRATORY FLOW RATE MEASURED AT THE FINAL VISIT WAS SIGNIFICANTLY HIGHER (P <.01) IN THE GROUP USING THE JET SPACER THAN IN PATIENTS USING THE STANDARD ACTUATOR. BETA 2- AGONIST CONSUMPTION DECREASED IN BOTH GROUPS. THE NUMBER OF PATIENTS WITH A NORMAL RESPONSE TO ACTH WAS SIGNIFICANTLY HIGHER (P <.01) IN THE JET GROUP THAN IN THE STANDARD ACTUATOR GROUP; CONCOMITANT URINARY CORTISOL EXCRETION DECREASED SIGNIFICANTLY (P <.05) IN THE STANDARD ACTUATOR GROUP. LOCAL IRRITATION WAS REPORTED BY 1 PATIENT IN THE JET GROUP AND BY 2 PATIENTS IN THE STANDARD ACTUATOR GROUP. USE OF THE NEW JET SPACER WAS FOUND TO REDUCE THE POTENTIAL FOR ADRENAL SUPPRESSION AND INCREASE THE EFFICACY OF HIGH-DOSE INHALED BECLOMETHASONE DIPROPIONATE GIVEN TO ADULTS WITH ASTHMA.

9 ADV THER JUL-AUG;13(4): ANNO: ISBN: SINDROMI RINOBRONCHIALI G.GIRBINO A. AVELLINO D.PASSALI E. POZZI D. OLIVIERI IL PUNTO SU: ALLERGIA ED INFIAMMAZIONE DELLE VIE AEREE: ENTITÀ PARALLELE O CONVERGENTI? SCIENTIC PRESS ISSN ANNO: ISBN: INSUFFICIENZA RESPIRATORIA F. ANDO P. MICALI BELLINGHIERI G. GIRBINO IN A.R. ANTONELLI A. BISETTI A. FERRARA G.GARETTI G. GIRBINO V. GRASSI CF MARCHIONNI, D. PASSALI A. SERRA IN FISIOLOGIA E FISIOPATOLOGIA DEL TRATTO RESPIRATORIO INTEGRATO- ULACOT EDIZIONE SCIENTIFICHE VALEAS ANNO: ISBN: COMPLESSO BRONCHITE ENFISEMA G. GIACOBBE, A.AVELLINO G. GIRBINO IN A.R. ANTONELLI A. BISETTI A. FERRARA G.GARETTI G. GIRBINO V. GRASSI CF MARCHIONNI D. PASSALI A. SERRA IN FISIOLOGIA E FISIOPATOLOGIA DEL TRATTO RESPIRATORIO INTEGRATO- ULACOT EDIZIONE SCIENTIFICHE VALEAS ANNO: ISBN: LA SINDROME ASMATICA F. ANDO G. RUFFINO M. CAZZOLA G. GIRBINO IN A.R. ANTONELLI A. BISETTI A. FERRARA G.GARETTI G. GIRBINO V. GRASSI CF MARCHIONNI D. PASSALI A. SERRA IN FISIOLOGIA E FISIOPATOLOGIA DEL TRATTO RESPIRATORIO INTEGRATO- ULACOT EDIZIONE SCIENTIFICHE VALEAS ANNO: ISBN: SINDROMI TUSSIGENE G. GIRBINO A. TOLISANO F. BARRECA A.R. ANTONELLI A. BISETTI A. FERRARA G.GARETTI G. GIRBINO V. GRASSI CF MARCHIONNI D. PASSALI A. SERRA IN FISIOLOGIA E FISIOPATOLOGIA DEL TRATTO RESPIRATORIO INTEGRATO-ULACOT EDIZIONE SCIENTIFICHE VALEAS ANNO: ISBN: ECOTOSSICOLOGIA RESPIRATORIA G.GIRBINO A. VADALA F. BARRECA A. TOLISANO IN A.R. ANTONELLI A. BISETTI A. FERRARA G.GARETTI G. GIRBINO V. GRASSI CF MARCHIONNI D. PASSALI A. SERRA IN FISIOLOGIA E FISIOPATOLOGIA DEL TRATTO RESPIRATORIO INTEGRATO- ULACOT EDIZIONE SCIENTIFICHE VALEAS ANNO: ISBN: LE PNEUMOPATIE DA FATTORI AMBIENTALI G. GIRBINO F ANDO G. FIORELLO G. QUATTRONE IN AGGIORNAMENTO MEDICINA CLINICA: DIAGNOSTICA E TERAPIA CG EDIZIONE MEDICO SCIENTIFICHE VOL. III ANNO: ISBN: EFFECT OF THE SELECTIVE 5-HT2 ANTAGONIST KETANSERIN ON ADENOSINE-INDUCED BRONCHOCONSTRICTION IN ASTHMATIC SUBJECTS.

10 CAZZOLA M, MATERA MG, SANTANGELO G, ASSOGNA G, D'AMATO G, ROSSI F, GIRBINO G. IN EIGHT ASTHMATIC SUBJECTS A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WAS PERFORMED TO INVESTIGATE THE EFFECT OF INHALED KETANSERIN, A 5-HT2 RECEPTOR BLOCKING AGENT, IN A DOSE OF 10 MG GIVEN 30 MIN BEFORE TEST, ON ADENOSINE-INDUCED BRONCHOSPASM. THE PROTECTIVE EFFECT OF KETANSERIN WAS SIGNIFICANT IN ALL PATIENTS, EVEN THOUGH IT ALTERED BASAL BRONCHOMOTOR TONE IN ONLY TWO SUBJECTS. ON THE CONTRARY, KETANSERIN DID NOT INHIBIT HISTAMINE-INDUCED BRONCHOCONSTRICTION IN FOUR OF THESE EIGHT ASTHMATICS, EVEN THOUGH IT MODIFIED SENSITIVITY AND REACTIVITY IN ONE OF THEM. THE RESULTS SUGGEST THAT KETANSERIN INFLUENCE ON ADENOSINE BRONCHIAL REACTIVITY AND SENSITIVITY WAS NOT DUE TO THE BRONCHODILATOR EFFECT OF KETANSERIN ITSELF OR TO ITS ANTIHISTAMINIC ACTIVITY. WE HAVE NO CERTAIN EXPLANATION FOR THE INHIBITION OF ADENOSINE- INDUCED BRONCHOCONSTRICTION ELICITED BY KETANSERIN. IT IS POSSIBLE THAT 5-HT MAY PLAY, AT LEAST IN PART, A ROLE AS MEDIATOR OF ADENOSINE-INDUCED BRONCHOCONSTRICTION. IMMUNOPHARMACOLOGY JAN-FEB;23(1):21-8. ANNO: ISBN: BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA: TRATTAMENTO AMBULATORIALE G. GIRBINO M. CAZZOLA ESI STAMPA MEDICA, 1999 ISBN ANNO: ISBN: INFLUENCE OF SULBACTAM PLUS AMPICILLIN ON THEOPHYLLINE CLEARANCE. CAZZOLA M, SANTANGELO G, GUIDETTI E, MATTINA R, CAPUTI M, GIRBINO G. THE EFFECT OF SULBACTAM/AMPICILLIN (500 MG/1000 MG) EVERY 12 HOURS TAKEN FOR SEVEN DAYS ON THE STEADY-STATE PHARMACOKINETICS OF THEOPHYLLINE WAS STUDIED AMONG 12 PATIENTS SUFFERING FROM CHRONIC OBSTRUCTIVE PULMONARY DISEASE. THEOPHYLLINE CONCENTRATIONS WERE MEASURED SERIALLY FOR 12 H BY THE METHOD OF POLARIZED IMMUNOFLUORESCENCE (ABBOTT TDX SYSTEM). NO INFLUENCE OF SULBACTAM/AMPICILLIN WAS DETECTABLE ON THE THEOPHYLLINE HALF-LIFE, CLEARANCE OR VOLUME OF DISTRIBUTION. IT WAS CONCLUDED THAT BOTH DRUGS COULD BE ADMINISTERED CONCOMITANTLY WITHOUT ANY DOSAGE ADJUSTMENT OF THEOPHYLLINE. INT J CLIN PHARMACOL RES. 1991;11(1):11-5. ANNO: ISBN: PNEUMOCONIOSI ED ALTRE MALATTIE PROFESSIONALI DEL POLMONE G. GIRBINO POLMONE IN L. CARRATU, E. CATENA C. GRASSI MANUALE DI MALATTIE DELL APPARATO RESPIRATORIE MASSON EDITRICE MILANO ISBN X ANNO: ISBN: A NEW ANTI-INFLAMMATORY--ANALGESIC--ANTIPYRETIC FOR THE TREATMENT OF ACUTE DISEASE OF THE BRONCHI GIRBINO G, OLIANI C, LAURIELLO G, CONDOLUCI M. SIXTY ADULT PATIENTS, 31 MEN AND 29 WOMEN, AGED 44 TO 60, AND AFFECTED BY ACUTE BRONCHITIS OF PROBABLE BACTERIAL AETIOLOGY WERE RANDOMLY DIVIDED INTO 3 GROUPS OF 20 AND TREATED RESPECTIVELY WITH: 1) MORNIFLUMATE (ONE 700 MG TABLET TWICE A DAY) + AMOXICILLIN (ONE 1 G TABLET TWICE A DAY); 2) FEPRAZONE (ONE 200 MG TABLET TWICE A DAY) + AMOXICILLIN (ONE 1 G TABLET TWICE A DAY); 3) AMOXICILLIN (ONE 1 G TABLET TWICE A DAY). MEAN THERAPY DURATION WAS 9 DAYS. THE ACTION OF THE DRUGS UNDER STUDY WAS ASSESSED BY OBJECTIVE CHEST EXAMINATION AND BY EVALUATING THE MODIFICATIONS OF COUGH INTENSITY AND FREQUENCY, CHEST PAIN EXPECTORATING DIFFICULTY, AMOUNT OF EXPECTORATION, BODY TEMPERATURE. THE OVERALL ASSESSMENTS WERE COMPLETED BY SIDE-EFFECT RECORDING AND BY LABORATORY EXAMINATIONS CARRIED OUT AT THE BEGINNING AND END OF THE STUDY. CHECKS WERE MADE REGULARLY ON ADMISSION, AND IN THE 3RD, 5TH, 7TH AND LAST DAY OF THERAPY. THE ABOVE MENTIONED PARAMETERS SHOWED A QUICKER REGRESSION OF BRONCHIAL INFLAMMATION IN THE SUBJECTS TREATED ALSO WITH THE ANTIINFLAMMATORY DRUG COMPARED TO THOSE TREATED ONLY WITH THE ANTIBIOTIC. FURTHERMORE, IN THE SUBJECTS TREATED WITH MORNIFLUMATE SUCH IMPROVEMENT WAS MORE RAPIDLY ACHIEVED COMPARED TO THOSE WHO RECEIVED FEPRAZONE. THE ANALGESIC AND ANTIPYRETIC EFFECTS OF MORNIFLUMATE WERE ALSO REMARKABLE. ALL TESTED DRUGS WERE WELL TOLERATED.

11 RIV EUR SCI MED FARMACOL DEC;12(6): ANNO: ISBN: CIPROFLOXACIN IN THE TREATMENT OF BRONCHOPULMONARY INFECTIONS GIRBINO G, GIACOBBE G, QUATTRONE G, FIORELLO G. CIPROFLOXACIN WAS GIVEN ORALLY IN DOSAGES OF 250 MG OR 500 MG EVERY 12 HOURS FOR A PERIOD OF 8-13 DAYS. MOST PATIENTS HAD CHRONIC BRONCHITIS IN THE ACUTE STAGE. THE FAVOURABLE RESULTS ACHIEVED AND THE COMPLETE ABSENCE OF SIDE EFFECTS SHOW THAT CIPROFLOXACIN IS A USEFUL DRUG IN THE TREATMENT OF RESPIRATORY TRACT INFECTIONS. RIV EUR SCI MED FARMACOL AUG-OCT;12(4-5): ANNO: ISBN: BACTERIAL ISOLATES AND CIGARETTE SMOKING IN PATIENTS WITH CHRONIC BRONCHITIS: RESULTS FROM AN ITALIAN MULTICENTER SURVEY. CAZZOLA M, ARIANO R, GIOIA V, MANCINI V, RIMOLDI R, SCALA G, SCOCCIA S, GIRBINO G PATIENTS WHO WERE CIGARETTE SMOKERS SUFFERING EXACERBATIONS OF CHRONIC BRONCHITIS WERE EXAMINED IN EIGHT OUTPATIENT CLINICS IN FIVE REGIONS OF ITALY, THREE FROM THE SOUTH (CAMPANIA, 82 PATIENTS; SICILY, 82 PATIENTS; AND PUGLIA, 29 PATIENTS) AND TWO FROM NORTH (LOMBARDY, 33 PATIENTS; AND LIGURIA, 50 PATIENTS). HAEMOPHILUS INFLUENZAE WAS THE MOST FREQUENTLY ISOLATED BACTERIUM IN THE PATIENTS' SPUTUM (IN 30% OF THE TOTAL GROUP), FOLLOWED BY STREPTOCOCCUS PNEUMONIAE (IN 20%), STAPHYLOCOCCUS AUREUS (IN 25%), AND BRANHAMELLA CATARRHALIS (IN 7%). H. INFLUENZAE WAS THE MOST COMMON BACTERIUM IN THE SOUTH (IN 37%) AND S AUREUS IN THE NORTH (IN 13%). SMOKING INDEX SCORES (NUMBER OF CIGARETTES SMOKED DAILY X YEARS OF SMOKING) WERE 827 IN PATIENTS IN WHOM H INFLUENZAE WAS ISOLATED; 691 IN PATIENTS WITH S AUREUS; 599 IN PATIENTS WITH S PNEUMONIAE; 542 IN PATIENTS WITH B CATARRHALIS; AND 446 IN PATIENTS IN WHOM NO ISOLATES WERE FOUND. PULMONARY FUNCTION WAS MOST SEVERELY DECREASED IN PATIENTS POSITIVE FOR H INFLUENZAE AND S AUREUS. THE RESULTS INDICATE AN ASSOCIATION BETWEEN HEAVY CIGARETTE SMOKING AND LOWER RESPIRATORY TRACT INFECTIONS THAT IS INFLUENCED BY REGIONAL DIFFERENCES. CLIN THER MAR-APR;12(2): ANNO: ISBN: PENETRATION OF CEFONICID INTO HUMAN LUNG TISSUE AND LYMPH NODES. CAZZOLA M, POLVERINO M, GUIDETTI E, SANTANGELO G, PAIZIS G, MONACO G, D'AMATO G, GIRBINO G. THE PRESENT STUDY WAS UNDERTAKEN IN ORDER TO INVESTIGATE THE PENETRATION OF CEFONICID, A LONG-ACTING PARENTERAL CEPHALOSPORIN, WITH ENHANCED ACTIVITY AGAINST MOST GRAM-POSITIVE AND GRAM-NEGATIVE PATHOGENS, INTO HUMAN LUNG TISSUE AND LYMPH NODES IN PATIENTS UNDERGOING OPEN THORACOTOMY. SAMPLES OF LUNG TISSUE, LYMPH NODES AND SERUM WERE OBTAINED AT VARIOUS TIMES AFTER A SINGLE INTRAMUSCULAR DOSE OF 1 G. THE CONCENTRATION OF CEFONICID WAS ASSAYED BY AN AGAR DIFFUSION METHOD WITH BACILLUS SUBTILIS USED AS THE TEST ORGANISM. THE MEAN CONCENTRATIONS OF CEFONICID IN SERUM AT 2, 4, 8, 12 AND 24 H AFTER THE INJECTION WERE 91.5, 66.1, 35.7, 21.8 AND 2.9 MICROGRAMS/ML, RESPECTIVELY. THE MEAN LEVELS OF CEFONICID INTO THE HILAR LYMPH NODES AT THE SAME TIMES WERE 22.3, 18.7, 12.0, 6.9 AND 1.5 MICROGRAMS/ML, RESPECTIVELY, WHILE ITS CONCENTRATIONS IN LUNG TISSUE WERE LOWER THAN THOSE IN LUNG LYMPH NODES UP TO THE 12TH HOUR (12.1, 14.6, 7.8, 5.4 AND 1.9 MICROGRAMS/ML, RESPECTIVELY). OUR RESULTS SHOW THAT CEFONICID WAS WELL DISTRIBUTED IN INTERSTITIAL FLUID FROM WHICH PULMONARY LYMPH IS FORMED AND THAT ITS CONCENTRATIONS IN LUNG TISSUE AND LYMPH NODES WERE SUFFICIENT TO INHIBIT MOST PATHOGENS INVOLVED IN RESPIRATORY TRACT INFECTIONS. THIS FINDING WAS CONSIDERED IMPORTANT, BECAUSE IT DEMONSTRATED THAT THE HIGH BINDING BY PLASMA PROTEIN OF CEFONICID DID NOT PREVENT IT FROM ENTERING LUNG TISSUE AND FLUIDS IN USEFUL QUANTITIES. CHEMOTHERAPY. 1990;36(5): ANNO: ISBN: ACUTE EFFECTS OF URAPIDIL ON AIRWAY RESPONSE IN HYPERTENSIVE PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. CAZZOLA M, SPINAZZI A, SANTANGELO G, STEINIJANS VW, WURST W, SOLLEDER P, GIRBINO G.

12 DRUGS. 1990;40 SUPPL 4:71-2. ANNO: ISBN: BRONCHOREACTIVITY INDUCED BY PHYSICAL EXERCISE AND METHACHOLINE IN CHILDREN WITH RHINITIS AND ALLERGIC ASTHMA. A COMPARATIVE STUDY BARBERIO G, RUGGERI C, PAJNO GB, MORABITO L, POLLICINO A, QUATTRONE G, ANDÒ F, GIRBINO G. BRONCHIAL PROVOCATION TESTS (TBP) ALLOW TO DETECT AIRWAYS HYPERREACTIVITY IN ASTHMATICS. TWENTY ASTHMATIC CHILDREN AND SIXTEEN RHINITICS UNDERWENT A STANDARD METHACHOLINE CHALLENGE AND A FREE RUNNING EXERCISE TEST ON TWO SEPARATE DAYS. METACHOLINE CHALLENGE POINTED OUT BRONCHIAL HYPERREACTIVITY IN 90% OF THE ASTHMATICS. AN EXERCISE INDUCED BRONCHOSPASM OCCURRED IN 70% OF THEM. TPB RESULTED POSITIVE ALSO IN 18% OF THE RHINITICS. OUR STUDY CONFIRMS DIAGNOSTIC USEFULNESS OF THE TBP AND A GOOD CORRELATION BETWEEN BOTH TESTS. PEDIATR MED CHIR MAR-APR;11(2): ANNO: ISBN: LA TOSSE : NUOVE ACQUISIZIONE DI FISIOPATOLOGIA E TERAPIA G. GIRBINO MONOGRAFIA ED. MINERVA MEDICA ANNO: ISBN: CLINICAL AND MICROBIOLOGICAL EVALUATION OF PRODRUG ANTIBIOTIC SCE A NEW CEPHALOSPORIN FOR ORAL USE. A COMPARATIVE OPEN RANDOMIZED STUDY VS CEFACLOR IN 50 PATIENTS WITH INFECTIONS OF THE MIDDLE OR LOWER RESPIRATORY TRACT] GIRBINO G, GIACOBBE G, FIORELLO G, CONDOLUCI M, MOLONIA N. ARCH MONALDI MAL TORACE NOV-DEC;43(6): ANNO: ISBN: IL POLMONE SENILE E LE MALATTIE DELL APPARATO RESPIRATORIO NELL ANZIANO G.GIRBINO F. FERRARA IN G. SQUADRITO, D. CERUSO. V. NICITA-MAURO GERIATRIA OGGI, EDITORIALE BIOS COSENZA ISBN ANNO: ISBN: PHYSIOPATHOLOGICAL RATIONALE AND CLINICAL AIMS OF THE USE OF A COMBINATION OF CEFUROXIME AND N-ACETYLCYSTEINE IN PNEUMOLOGY. GIRBINO G, GIACOBBE G, ARSENA A, FERRARA F. THE TRIAL POPULATION CONSISTED OF 50 PATIENTS SUFFERING FROM ACUTE EXACERBATIONS OF CHRONIC BRONCHIAL DISEASE PROCESSES. FORTY PATIENTS WERE TREATED WITH AN EXTEMPORE COMBINATION OF CEFUROXIME AND N-ACETYLCYSTEINE AT THE DOSES OF 2 G AND 600 MG/DAY RESPECTIVELY IN TWO I.M. ADMINISTRATIONS. THE OTHER 10 PATIENTS WERE TREATED WITH N- ACETYLCYSTEINE ALONE AT THE SAME DOSE. RESPIRATORY TRACT CLINICAL AND INSTRUMENTAL PARAMETERS WERE INVESTIGATED, AND BACTERIOLOGICAL TESTS WERE PERFORMED ON SPUTUM SAMPLES BEFORE AND AFTER TREATMENT. TOLERANCE OF THE TREATMENT WAS ASSESSED ON THE BASIS OF MEASUREMENT OF BLOOD-CHEMISTRY PARAMETERS. INT J CLIN PHARMACOL THER TOXICOL MAR;23(3): ANNO: ISBN: POSITION OF CEFTAZIDIME IN RESPIRATORY DISEASES. ANDO' F, GIRBINO G, FERRARA F. TWENTY PATIENTS (10 MALES AND 10 FEMALES), RANGING IN AGE FROM 53 TO 81 YEARS, WERE TREATED WITH CEFTAZIDIME, 2-3 G/DAY I.M., FOR 12 TO 15 DAYS. ALL PATIENTS WERE SUFFERING FROM MODERATE TO SEVERE INFECTIONS OF THE LOWER RESPIRATORY TRACT (6 CASES OF PNEUMONIA AND 14 CASES OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS). IN ADDITION, ALMOST ALL PATIENTS PRESENTED SEVERE LOCAL AND GENERAL PREDISPOSING FACTORS (THREE PATIENTS WITH LUNG CANCER, TWO WITH BRONCHIECTASIS AND 14 WITH RESPIRATORY INSUFFICIENCY). THE AETIOLOGICAL AGENTS RESPONSIBLE FOR THE INFECTIONS WERE MAINLY

13 GRAM-NEGATIVE BACTERIA (6 KLEBSIELLA PNEUMONIAE, 4 HAEMOPHILUS INFLUENZAE, 4 PSEUDOMONAS AERUGINOSA AND 3 PROTEUS STRAINS). THE CLINICAL AND MICROBIOLOGICAL RESULTS OF THE TREATMENT WERE GOOD. WITH THE EXCEPTION OF ONE CASE OF MACULOPAPULAR RASH, NONE OF THE PATIENTS COMPLAINED OF ADVERSE REACTIONS AND NO TOXIC EFFECTS WERE OBSERVED. DRUGS EXP CLIN RES. 1985;11(6): ANNO: ISBN: BRONCHOPULMONARY LESIONS CAUSED BY ASPIRATION (CASE REPORTS) GIRBINO G, ROMANO C, MARTINO L, FERRARA F. ARCH MONALDI JUL-AUG;39(4): ANNO: ISBN: LE PNEUMOCONIOSI G. BABOLINI, G. GIRBINO; G. BAGNATO, G. GIACOBBE IN AGGIORNAMENTO DEL TRATTATO MEDICINA CLINICA : DIAGNOSTICA E TERAPIA. CG EDIZIONI MEDICO-SCIENTIFICHE ANNO: ISBN: INVOLVEMENT OF THE LUNG IN RECKLINGHAUSEN'S MULTIPLE NEUROFIBROMATOSIS (DESCRIPTION OF A CASE) GIRBINO G, ROMANO C, ANDÒ F, MARTINO L. ARCH MONALDI SEP-DEC;38(5-6): ANNO: ISBN: MULTICENTER CLINICAL STUDY ON THE DELAYED USE OF IPRATROPIUM-FENOTEROL IN BRONCHO- OBSTRUCTIVE PATHOLOGY BABICH S, BARIFFI F, BISETTI A, CARNIMEO N, CAVALLI A, CORDA M, DE MICHELE G, GIRBINO G, MANCINI PA, MELICA A, ET AL. ARCH MONALDI SEP-DEC;38(5-6): ANNO: ISBN: LETOSTEINE IN CHRONIC BRONCHOPATHY GIRBINO G, BAGNATO GF, GIACOBBE G. ARCH MONALDI JUL-AUG;38(4): ANNO: ISBN: FACTORS OF CHRONICITY CAUSED BY A DEFICIT OF T CELLS IN BACTERIAL AND MYCOTIC BRONCHOPATHIES. TRIALS ON IMMUNOMODULATION BAGNATO G, GIRBINO G. ARCH MONALDI MAY-JUN;37(3-4): ANNO: ISBN: RESPIRATORY ALLERGY LINKED TO MYCOLOGICAL FLORA IN THE LUNG BABOLINI G, GIRBINO G, COSTA AL. BRONCHOPNEUMOLOGIE. 1980;30(4): ANNO: ISBN: LE MALFORMAZIONI POLMONARI CONGENITE G. BABOLINI, G. GIRBINO, BAGNATO, G. GIACOBBE

14 IN CAPITOLO DEL MANUALE DI MEDICINA INTERNA DIRETTO DA P. LARIZZA. VOL. V, ANNO: ISBN: LE PNEUMOCONIOSI G. BABOLINI, G. GIRBINO; G. BAGNATO, G. GIACOBBE IN CAPITOLO DEL TRATTATO MEDICINA CLINICA : DIAGNOSTICA E TERAPIA. CGEDIZIONI MEDICO- SCIENTIFICHE: VOL. III ANNO: ISBN: THE CLINICAL ASPECTS OF THE PUMICE-STONE PNEUMOCONIOSIS BABOLINI G, INFERRERA C, GIRBINO G. SCAND J RESPIR DIS SUPPL. 1978;102: ANNO: ISBN: L EMOTISSI OGGI G. BABOLINI, G. GIRBINO G.F. BAGNATO, G. GIACOBBE IN G. SPINA C. BONSIGNORE LA PATOLOGIA RESPIRATORIA C.G. EDIZIONE MEDICO SCIENTIFICHE VOL. II ANNO: ISBN: PERFUSION SCINTIGRAPHY IN THE STUDY OF DYSFUNCTIONAL LUNG PATHOLOGY CAUSED BY VARIOUSLY TREATED TUBERCULAR PATHOLOGICAL PROCESSES BRUSCAGNIN G, POGGIOPOLLINI M, GIRBINO G. ARCH MONALDI SEP-DEC;32(5-6): ANNO: ISBN: BRONCHIOLAR AND ALVEOLAR SCANNING WITH AU 198. INDICATIVE EVALUATION OF CLEARANCE TIME BABOLINI G, BLANDINO G, CAPONE M, BONANNO N, GIRBINO G. ARCH MONALDI SEP-DEC;31(5-6): ANNO: ISBN: RESPIRATORY, CARDIOLOGICAL AND METABOLIC FUNCTIONAL STUDIES OF THE EFFECTS OF SALBUTAMOL IN BRONCHOPATHIC PATIENTS OF VARIOUS AGES BABOLINI G, GEMELLI M, CAPONE M, COGLITORE G, MINISTERI S, GIRBINO G, PINIZZOTTO G, BARBERIO G. MINERVA MED MAR 31;67(16): ANNO: ISBN: CAPACITÀ E COMPETENZE PERSONALI HA PERCORSO TUTTI I GRADINI SOTTO IL PROFILO UNIVERSITARIO E QUELLO ASSISTENZIALE DELLA CARRIERA PRESSO LA CLINICA MALATTIE RESPIRATORIE DELL'UNIVERSITÀ DI MESSINA SIA QUANDO ERA ISTITUTO DI MALATTIE RESPIRATORIO SIA NELL'AMBITO DEL DIPARTIMENTO UNIVERSITARIO E DEL DIPARTIMENTO ASSISTENZIALE INTEGRATO SVOLGENDO LE ATTIVITÀ ISTITUZIONALI COMPRESI I PERIODI GUARDIA E TUTTI GLI OBBLIGHI ASSISTENZIALI PREVISTI DALLE NORME VIGENTI. HA CONDOTTO E PORTATO A TERMINE SPERIMENTAZIONI CLINICHE DI FASE II, III, IV E DI INDAGINI OSSERVAZIONALI. HA IDEATO, MESSO A PUNTO E REALIZZATO PROGRAMMI DI FORMAZIONE CONTINUA ORIGINALI A LIVELLO NAZIONALE, QUALI ESPERRIENXZE DI EMERGENZE RESPIRATORIE SU SIMULATORI ELETTRONICI, VIDEOENDOSCOPIA SU SIMULATORI ELETTRONICI, SIMULAZIONE E MICROSIMULAZIONE DI CASI CLINICI, PROGRAMMAI DI AGGIORNAMENTO IN IMAGING TORACICO.HA ATTIVATO UN SETTORE DI BRONCOLOGIA MEDICA SIN DAL 1977, DUE POSTI LETTO DI VENTILAZIONE MECCCANICA NON INVASIVA MESSA A PUNTO E REALIZZAZIONE DI TECNCIHE DI FISIOPATOLOGIA RESPIRATORIA INNOVATIVE QUALI L'ESAME DELL'ESALATO, DELL'OSSIDO NITRICO ESALATO, WALKING TEST. HA ATTIVATO UN PRESIDIO OPERATIVO PER IPROGRAMMI DI PREVENZIONE E CURA

15 DELL'ASMA BRONCHIALE APPROVATO DAL CONSIGLIO DI AMMINISTRAZIONE DELLA UNIVERSITÀ DI MESSINA ED UN CENTRO PER I DISTURBI RESPIRATORI SONNO-CORRELATI. PRIMA LINGUA ITALIANO ALTRE LINGUE INGLESE Capacità di lettura ECCELLENTE Capacità di scrittura BUONO Capacità di espressione orale Buono FRANCESE Capacità di lettura ECCELLENTE Capacità di scrittura ECCELLENTE Capacità di espressione orale BUONO CAPACITÀ E COMPETENZE RELAZIONALI SOCIETÀ ITALIANA DI PNEUMOLOGIA SOCIETÀ ITALIANA DI ENDOSCOPIA TORACICA SOCIETÀ ITALIANA DI MEDICINA RESPIRATORIA ACCADEMIA PELORITANA DEI PERICOLANTI NEW YORK ACADEMY OF SCIENCE FELLOW DELL'AMERICAN COLLEGE OF CHEST PHYSICIANS EUROPEAN RESPIRATORY SOCIETY AMERICAN THORACIC SOCIETY ASSOCIAZIONE ITALIANA INFORMATICA MEDICA SOCIETÀ ICAMM (ITALIAN COLLEGE OF APPLIED MOLECULAR MEDICINE) SOCIO ONORARIO DELL AISA (ASSOCIAZIONE ITALIANA STUDI SULL ASMA) MEDITERRANEAN THORACIC SOCIETY CONSIGLIO DIRETTIVO DELLA SOCIETÀ ITALIANA DI PNEUMOLOGIA CONSIGLIO DIRETTIVO DELLA SOCIETÀ ITALIANA DI ENDOSCOPIA TORACICA CONSIGLIO DIRETTIVO SOCIETÀ ITALIANA DI MEDICINA RESPIRATORIA CONSIGLIO DIRETTIVO UIP (UNIONE ITALIANA PER LA PNEUMOLOGIA) GOVERNOR DELL'AMERICAN COLLEGE OF CHEST PHYSICIANS PRESIDENTE DELLA SEZIONE SICILIANA DELLA ASSOCIAZIONE ITALIANA INFORMATICA MEDICA SEGRETARIO REGIONALE A.L.I.R. (ASSOCIAZIONE PER LA LOTTA CONTRO L INSUFFICIENZA RESPIRATORIA) COLLEGIO DOCENTI DI MALATTIE RESPIRATORIE COMITATO ESECUTIVO SYRIAN-ITALIAN ASSOCIATION OF CHEST DISEASES DELEGATO NAZIONALE COMITATO ESECUTIVO DELLA MEDITERRANEAN THORACIC SOCIETY PRESIDENTE SOCIETÀ ITALIANA MEDICINA RESPIRATORIA (SIMER) 2003-AD OGGI PESIDENTE DELLA MEDITERRANEAN THORACIC SOCIETY (MTS) 2004-AD OGGI COMPONENTE COMITATO ESECUTIVO DELLA FEDERAZIONE ITALIANA PER LE MALATTIE SOCIALI E LA TUBERCOLOSI ALTO PATROCINIO DELLA PRESIDENZA DELLA REPUBBLICA PRESIDENTE DELLA FONDAZIONE UNIONE ITALIANA PER LA PNEUMOLOGIA 2007 AD OGGI VICE PRESIDENTE VICARIO DELLA FEDERAZIONE ITALIANA CONTRO LE MALATTIE POLMONARI SOCIALI E LA TUBERCOLOSI CONSIGLIO SUPERIORE DI - COMPONENTE DELLA COMMISSIONE DELLE VARI SPECIALITÀ PER LA DEFINIZIONE DELLE SPECIFICHE ATTIVITÀ PROFESSIONALI PERSONALE SANITARIO PER INCARICO DI DIREZIONE DI STRUTTURA COMPLESSA COORDINAMENTO BOARD SCIENTIFICO PER LO STUDIO E LA REALIZZAZIONE DI PROGETTI PER IL CONTROLLO DELL ASMA BRONCHIALE COORDINAMENTO BOARD SCIENTIFICO PROGETTO DI "COMUNICAZIONE EFFICACE FRA MEDICO E PAZIENTE: ASPETTO STRATEGICO NELLA CORRETTA GESTIONE DELLE PATOLOGIE OSTRUTTIVE RESPIRATORIE RAPPRESENTANTE DELLE SOCIETÀ SCIENTIFICHE PNEUMOLOGICHE ITALIANE AL FORUM DELLE SOCIETÀ PNEUMOLOGICHE EUROPEE PRESSO L ERS (EUROPEAN RESPIRATORY SOCIETY) APRILE 2007 ESPERTO AL CONSIGLIO SUPERIORE DI (AREA PNEUMOLOGICA) COMITATO SCIENTIFICO DELLA RIVISTA ARCHIVIO MONADI PER LA MALATTIE RESPIRATORIE COMITATO SCIENTICO DELLA RIVISTA OCCHIO CLINICO ADVISORY BOARD MONALDI ARCHIVES FOR CHEST DISEASES COMITATO SCIENTIFICO CENTRO STUDI MEDICINA CIVITAS HIPPOCRATICA COMITATO SCIENTIFICO DELLA RIVISTA GIORNALE ITALIANO DELLE MALATTIE DEL TORACE COMITATO SCIENTIFICO DELLA RIVISTA IJCI (INTERNATIONAL JOURNAL OF CLINICAL INVESTIGATION) COMITATO SCIENTIFICO A.S.M.A. COMITATO EDITORIALE DELL EDIZIONE ITALIANA CHEST COMITATO D ONORE DELL ALKMEON INTERNATIONAL ACADEMY CAPACITÀ E COMPETENZE ORGANIZZATIVE SU PIANO SCIENTIFICO SI È OCCUPATO PREVALENTEMENTE DI : BRONCOLOGIA CLINICA

16 FUNZIONALE FARMACOLOGIA CLINICA DELL APPARATO RESPIRATORIO ASPETTI IMMUNOLOGICI DELLA TUBERCOLOSI DANNO INVALIDANTE RESPIRATORIO DA AMBIENTE DIAGNOSTICA FUNZIONALE RESPIRATORIA AUTORE DI OLTRE 450 PUBBLICAZIONI SCIENTIFICHE SU RIVISTE NAZIONALI ED INTERNAZIONALI, DI 15 CAPITOLI CAPITOLI PNEUMOLOGICI NELL'AMBITO DI TRATTATI DI MEDICINA INTERNA, GERIATRIA E PNEUMOLOGIA. HA PARTECIPATO IN QUALITÀ DI RELATORE O MODERATORE AD OLTRE 600 CONVEGNI E CONGRESSI A CARATTERE NAZIONALE ED INTERNAZIONALE. HA ORGANIZZATO NUMEROSE MANIFESTAZIONI SCIENTIFICHE, CORSI E CONGRESSI TRA CUI CINQUE CONFERENZE INTERNAZIONALI E TRE CONGRESSI DELLE SOCIETÀ SCIENTIFICHE UFFICIALI ITALIANE CAPACITÀ E COMPETENZE TECNICHE. GESTIONE ED USO DEI SISTEMI DI ANALISI DELLA FUNZIONE RESPIRATORIA (ANALISI OSSIDO DI AZOTO E CONDENSATO ESPIRATI, PLETISMOGRAFIA, ANALISI DEI GAS IN MEZZI DIVERSI)VENTILAZIONE MECCANICA NON INVASIVA; BRONCOLOGIA ( BRONCOLAVAGGIO, BCONCOINSTILLAZIONE, BRONCOSCOPIA) OTTIMA CONOSCENZA DI VARI SISTEMI INFORMATIVI: WINDOWS 95/98/2000/ME/XP/VISTA E LINUX. OTTIMA CONOSCENZA DI VARI SOFTWARE APPLICATIVI: TORTOISECVS (CLIENT CVS), ADOBE PHOTO SHOP, PAINT SHOP PRO. BUONA CONOSCENZA DEI VARI PROGRAMMI DI STATISTICA TRA CUI SOFTWARE SPSS(STATISTICS BASE, SPSS REGRESSION, SPSS ADVANCED STATISTICS, SPSS CUSTOM TABLES, SPSS FORECASTING, SPSS EZ RFM, SPSS EXACT TESTS, SPSS DECISION TREES, SPSS CATEGORIES, SPSS DATA PREPARATION, SPSS MISSING VALUES, SPSS CONJOINT, SPSS COMPLEX SAMPLES, SPSS NEURAL NETWORKS, SPSS STATISTICS SERVER, AMOS, SPSS DATA ENTRY, SPSS VIZ DESIGNER, SAMPLEPOWER). OTTIMA CONOSCENZA DEL PACCHETTO MICROSOFT OFFICE (WORD, EXCEL, ACCESS, GROOVE, INFOPATH, POWER POINT, OUTLOOK, ONENOTE, PUBLISHER). PROGETTAZIONE E REALIZZAZIONI DI VARIE PRESENTAZIONI POWER- POINT RIGUARDANTI VARI ARGOMENTI DI PNEUMOLOGIA (ANATOMIA, FISIOLOGIA, FISIOPATOLOGIA, DIAGNOSTICA, CLINICA, TERAPIA, EPIDEMIOLOGIA) CAPACITÀ E COMPETENZE ARTISTICHE FOTOGRAFIA AD ALTO LIVELLO ALTRE CAPACITÀ E COMPETENZE PRINCIPALE INVESTIVAGOR IN NUMEROSE SPERIMENTAZIONI CLINICHE DI VARIO LIVELLO NEGLI ULTIMI CINQUE ANNI: STUDIO CLINICO NOVARTIS CFOR258F2402 (FORMOTEROLO) STUDIO CLINICO NOVARTIS CQAB149B2335S (INDACATEROLO) STUDIO CLINICO CHIESI CCD-0605-PR-0021 (BECLOMETHASONE DIPROPIONATE 200 UG PLUS FORMOTEROL 6 UG/ACTUATION) STUDIO CLINICO BAYER (MOXIFLOXACINA E.V.) ISACCO(PROGETTO OSSERVAZIONALE BPCO, CAP, ASMA), SIRIO(ASMA),OPA(ASMA), IRESSA(TERAPIA CON DEFINITI IN PAZIENTI CON TUMORE NON A PICCOLE CELLULE IN FASE AVANZATA ), INOC(ITALIAN NITRIC OXIDE CLUB, PER LA VALUTAZIONE DELL OSSIDO NITRICO NELL ESPIRATO DI PAZIENTI AFFETTI DA ASMA BRONCHIALE), SMART(A PAN-EUROPEAN OPEN RANDOMISED STUDY COMPARING THE EFFICACY AND COST-EFFECTIVENESS OF SYMBICORT MAINTENANCE AND RELIEVER THERAPY (SYMBICORT SMART) USING A MAINTENANCE DOSE OF SYMBICORT 160/4.5µG OF 1 OR 2 INHALATIONS TWICE DAILY IN THE TREATMENT OF PERSISTENT ASTHMA), PRISMA(PROSPECTIVE STUDY ON ASTHMA CONTROL, PER VALUTARE IL GRADO DI CONTROLLO DELLA PATOLOGIA ASMATICA), BPCO3( PREVALENZA, DISTRIBUZIONE E GRAVITÀ DELLA BPCO IN ITALIA), MART2( STUDIO CLINICO DI 48 SETTIMANE, MULTICENTRICO, MULTINAZIONALE, RANDOMIZZATO, IN DOPPIO CIECO, A 2 GRUPPI PARALLELI, PER CONFRONTARE L EFFICACIA DI FOSTER UTILIZZATO COME TERAPIA DI MANTENIMENTO E TERAPIA AL BISOGNO VS UNA DOSE FISSA DI FOSTER UTILIZZATO COME TERAPIA DI MANTENIMENTO + SALBUTAMOLO UTILIZZATO COME TERAPIA AL BISOGNO IN PAZIENTI ASMATICI DI ETÀ MAGGIORE O UGUALE A 18 ANNI ), BRONCHOVAXOOM.(BV 2007/02_COPD MULTICENTRE, DOUBLE-BLIND, PLACEBO- CONTROLLED, RANDOMISED CLINICAL STUDY OF BRONCHO-VAXOM (BRONCHO- MUNAL) FOR THE PROTECTION FROM ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATENTE O PATENTI PATENTE B

17 ULTERIORI INFORMAZIONI ONORIFICENZE: 1988: MEDAGLIA D ORO AL MERITO SCIENTIFICO CARLO FORLANINI 1998: PREMIO ANASSILAOS PER LA RICERCA1998 ALLEGATI 1) ABSTRACT CONGRESSI 2) CAPITOLI IN TRATTATI 3) LAVORI IN ESTESO Esci CV